medicine-products/protein-g-samples-pack-----13-od--3b--25-od-3b--50-od-per-sq--cm-25722-1/;msg90356
| We're sorry, that page (http://www.bio-medicine.org/medicine-products/protein-g-samples-pack-----13-od--3b--25-od-3b--50-od-per-sq--cm-25722-1/;msg90356) was not found. Search medicine products protein g samples pack 13 od 3b 25 od 3b 50 od per sq cm 25722 1 ;msg90356 at Google Search medicine products protein g samples pack 13 od 3b 25 od 3b 50 od per sq cm 25722 1 ;msg90356 at Yahoo Search medicine products protein g samples pack 13 od 3b 25 od 3b 50 od per sq cm 25722 1 ;msg90356 at Msn |
(Date:12/4/2009)...swire/ -- Stemline Therapeutics, Inc. today announ...3R targeting agents, SL-401 and SL-501, in both i...d leukemia (CML) have been selected for poster pre...he American Society of Hematology (ASH), to be hel...er will be presented by Stemline,s collaborators a...
(Date:12/3/2009)...wswire/ -- JourneyLite of Houston, LLC announced...atients a second surgical option, vertical sleeve...em that it currently performs. The first sleeve g... by surgeon partner, Matthew St. Laurent, MD on ... well. ,, The Vertical Sleeve Gastrectomy (also...
(Date:12/3/2009)...wswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC...n update on its European commercial launch of MuGa...a debilitating side effect of radiation treatment ...by Access, partner, SpePharm, in six European coun...reece and Sweden. Access is conducting pre-marketi...
(Date:12/3/2009)...ewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq:...company, today announced a voluntary recall of fiv...of the Attention-Deficit/Hyperactivity Disorder (A...action because some Daytrana patches do not meet o...emoval specification, and as a result, patients an...
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5[0] Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)[0] JourneyLite of Houston Now Offering Sleeve Gastrectomy[0] Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe[0] Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced
(Date:12/3/2009)...c. 3 Radiology imaging leader MEDR...ration capabilities at the November 2009 Radiology...t.PACS(TM) product, enabling the first radiology ...t release in the company,s newly branded Certegra...://www.newscom.com/cgi-bin/prnh/20091203/NE20631 ...
(Date:12/3/2009).... 3 Wound Management...rapidly growing provider of specialty medical prod... Industry Representative Association (HIRA) to ser...ing representative to market the company,s core Ce...IRA will market and sell Wound Management Technolo...
(Date:12/3/2009)...re-FirstCall/ -- Cardium Therapeutics (NYSE Amex: ...diary, Tissue Repair Company, submitted a 510(k) p...d Drug Administration (FDA) seeking marketing clea...sed on positive data from the Company,s recently c...submission with the FDA covers Excellagen XL(TM) ...
Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 1Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 2Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 1SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 2SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 4SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 5SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 6SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 7SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 8SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 9SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 10Combo Treatment May Ease Depression After Stroke 53891 1Combo Treatment May Ease Depression After Stroke 53891 2[0] MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009[0] Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up[0] Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
| Copyright © 2003-2007 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |